Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Poor quality product administered, Product temperature excursion issue
Clinical narrative: Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 003B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Feb-2021 at 2:02 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 21-Mar-2021 at 2:08 PM, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 24.28 years at first dose and 24.37 at second dose. Concomitant and treatment medications were not reported. On 09-Feb-2021, the vaccine with batch number 031L20A was moved to fridge. On 12-Feb-2021, 3 vials were moved to the clinic. On 12-Feb-2021 at 10 AM and 11 AM vials underwent temperature excursion with temperature of 35 degrees Fahrenheit. On 09-Feb-2021, the vaccine with batch number 031L20A was moved to fridge. On 13-Feb-2021, 30 vials were moved to the clinic. On 13-Feb-2021 at 9 AM vials underwent temperature excursion with temperature of 32 degrees Fahrenheit.  On 09-Feb-2021, the vaccine with batch number 031L20A was moved to fridge. On 13-Feb-2021, 30 vials were moved to the clinic. On 14-Feb-2021 at 9 AM to 2 PM vials underwent temperature excursion with temperature of 32 and 35 degrees Fahrenheit. The condition of vaccine prior to vaccination was not frozen. The vaccine beyond use date was reported as 10-Mar-2021. On 16-Mar-2021, the vaccine with batch number 003B21A was moved to fridge. On 21-Mar-2021, 10 vials were moved to the clinic. On 21-Mar-2021 at 9 AM, 10 AM and 11 AM vials underwent temperature excursion with temperature of 34, 32, 34 degrees Fahrenheit. The condition of vaccine prior to vaccination was not frozen. The vaccine beyond use date was reported as 15-Apr-2021. It was reported that, the storage condition at the time of the excursion was cooler storage during high-pace COVID-19 vaccination clinic. The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic. Temperature recordings were taken using a traceable temperature monitor at every hour. It was reported that, the patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021.   This case was linked to MOD-2022-566976 (Patient Link).